logo
Plus   Neg
Share
Email

Sequential Brands Q4 Loss Widens - Quick Facts

Sequential Brands Group, Inc. (SQBG.OB) reported fourth-quarter net loss attributable to common stockholders of $7.35 million or $3.00 per share, wider than $3.4 million or $1.41 per share in the previous year.

Excluding items, adjusted loss was $0.9 million or $0.37 per share, while the company posted a net income of $0.4 million or $0.16 per share in the prior-year quarter.

Loss from continuing operations for the recent quarter was $2.60 per share, compared to earnings of $0.16 per share a year ago.

Total revenues from continuing operations increased to $1.83 million from $0.4 million in the preceding year.

For the quarter, the company posted operating expenses totaling $7.95 million, significantly higher than $36 thousand in the prior year.

Commenting on the full year, Yehuda Shmidman, CEO of the company said, "2012 was a transformational year for the Company as we closed down our wholesale and retail operations and re-launched our Company under a new name, Sequential Brands Group, with a new business model, being a focused brand management company."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT